149 related articles for article (PubMed ID: 34241685)
1. Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study.
Tang QL; Wang DJ; Zhou S; Tao RZ
World J Urol; 2021 Dec; 39(12):4465-4470. PubMed ID: 34241685
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study.
Bayar G; Yavuz A; Cakmak S; Ofluoglu Y; Kilinc MF; Kucuk E; Aydın M
Int Urol Nephrol; 2020 May; 52(5):835-840. PubMed ID: 31873859
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Mirabegron as Medical Expulsive Therapy for Distal Ureteral Stones: A Prospective, Randomized, Double-Blinded, Controlled Study.
Morsy S; Nasser I; Aboulela W; Abdelazim MS; Ali H
Urol Int; 2022; 106(12):1265-1271. PubMed ID: 35100594
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of mirabegron in medical expulsive therapy.
Solakhan M; Bayrak O; Bulut E
Urolithiasis; 2019 Jun; 47(3):303-307. PubMed ID: 30078089
[TBL] [Abstract][Full Text] [Related]
5. Does mirabegron have a potential role as a medical expulsive therapy in the treatment of distal ureteral stones? A prospective randomized controlled study.
Samir M; Awad AF; Maged WA
Urologia; 2024 Feb; 91(1):136-140. PubMed ID: 37776033
[TBL] [Abstract][Full Text] [Related]
6. Adjunction of tamsulosin or mirabegron before semi-rigid ureterolithotripsy improves outcomes: prospective, randomized single-blind study.
Bayar G; Kilinc MF; Yavuz A; Aydın M
Int Urol Nephrol; 2019 Jun; 51(6):931-936. PubMed ID: 30989563
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.
Cai D; Wei G; Wu P; Huang Y; Che X; Zhang Y; Zhou Z; Kong G
Int J Clin Pract; 2022; 2022():2293182. PubMed ID: 35685505
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones.
Abdel-Kader MS; Sayed AM; Sayed SM; AbdelRazek M
Int Urol Nephrol; 2024 May; 56(5):1605-1610. PubMed ID: 38041752
[TBL] [Abstract][Full Text] [Related]
9. RE: mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study.
Keller EX; Devos B; De Coninck V
World J Urol; 2022 May; 40(5):1271-1272. PubMed ID: 35018496
[No Abstract] [Full Text] [Related]
10. Tamsulosin versus tadalafil as a medical expulsive therapy for distal ureteral stones: A prospective randomized study.
Kc HB; Shrestha A; Acharya GB; Basnet RB; Shah AK; Shrestha PM
Investig Clin Urol; 2016 Sep; 57(5):351-6. PubMed ID: 27617317
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron: A Novel and Promising Medical Expulsive Treatment for Ureteral Stones?
Urkmez A; Tokuc E; Topaktas R; Sahin A; Yuksel OH
J Coll Physicians Surg Pak; 2019 Jan; 29(1):73-74. PubMed ID: 30630575
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Ye Z; Zeng G; Yang H; Tang K; Zhang X; Li H; Li W; Wu Z; Chen L; Chen X; Liu X; Deng Y; Pan T; Xing J; Wang S; Cheng Y; Gu X; Gao W; Yang J; Zhang Y; Mi Q; Qi L; Li J; Hu W; Liang P; Sun Z; Xu C; Long Y; Liao Y; Liu S; Liu G; Xu X; He W; Chen Z; Xu H
Eur Urol; 2018 Mar; 73(3):385-391. PubMed ID: 29137830
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
18. Mirabegron for medical expulsive therapy of ureteral stones: a systematic review and meta-analysis.
Song H; Liang L; Liu H; Liu Y; Hu W; Zhang G; Xiao B; Fu M; Li J
Front Med (Lausanne); 2023; 10():1280487. PubMed ID: 38249979
[TBL] [Abstract][Full Text] [Related]
19. A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Chapple CR; Dvorak V; Radziszewski P; Van Kerrebroeck P; Wyndaele JJ; Bosman B; Boerrigter P; Drogendijk T; Ridder A; Van Der Putten-Slob I; Yamaguchi O;
Int Urogynecol J; 2013 Sep; 24(9):1447-58. PubMed ID: 23471546
[TBL] [Abstract][Full Text] [Related]
20. Tadalafil versus alpha blockers (alfuzosin, doxazosin, tamsulosin and silodosin) as medical expulsive therapy for < 10 mm distal and proximal ureteral stones.
Çelik S; Akdeniz F; Afsar Yildirim M; Bozkurt O; Gursoy Bulut M; Hacihasanoglu ML; Demir O
Arch Ital Urol Androl; 2018 Jun; 90(2):117-122. PubMed ID: 29974727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
